Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

TTUHSC researcher Srinivas Nandana, Ph.D., (left) and co-investigator Manisha Tripathi, Ph.D., received a grant from the U.S. Department of Defense to investigate the role of TBX2 in establishing the ...

Former President Joe Biden has been diagnosed with metastatic prostate cancer at age 82. The former president's office said he has an "aggressive form" of the cancer, which has spread to his bones.

This meta-analysis of 7 trials provides the highest level of evidence to date supporting MDT for selected patients with oligometastatic prostate cancer. Metastasis-directed therapy (MDT) prolongs ...

Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Hormone therapy, regardless of duration, after salvage radiation may delay metastasis and prostate cancer death. Both short- and long-course hormone therapy (HT) after postoperative radiation therapy ...